FAS Gamma Subunit Mapping for Targeted Enzyme Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing structural and mechanistic details of the iterative shuttling process in fatty acid synthase (FAS) are sparse, hindering biotechnological efforts and the understanding of its role in diseases like cancer and obesity.
Innovation Solution
Identification and characterization of a new gamma subunit (Tma17p) in the FAS protein complex, along with methods for purifying and recombinant polypeptides, and designing inhibitors for enzymes within the complex, such as ketoreductase, enoylreductase, and malonyl/palmitoyl transferase, to modulate fatty acid synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If structural studies are conducted to establish FAS complex architecture, then understanding of FAS structure is improved, but mechanistic and structural details of the iterative shuttling process remain sparse
Solution Approach 1:
The patent divides the FAS complex into discrete functional domains (KS, AT, DH, ER, KR, ACP, MPT) and identifies specific subunits (α-subunit, β-subunit, γ-subunit). This segmentation allows detailed structural characterization of each component while maintaining understanding of the overall complex architecture and iterative shuttling mechanism.
Solution Approach 2:
The patent identifies the γ-subunit (Tma17p) as an intermediary component that facilitates understanding of the iterative shuttling process. This previously unidentified subunit provides missing mechanistic details about how substrates are transferred between functional domains, bridging the gap between structural knowledge and functional mechanism.
2Reliability
If FAS is targeted for disease treatment, then therapeutic potential is improved, but lack of mechanistic details hinders inhibitor design
Solution Approach 1:
The patent identifies specific functional domains (KR, ER, MPT) within the FAS complex as potential drug targets. By focusing on local enzymatic activities rather than the entire complex, the patent reduces inhibitor design complexity while maintaining therapeutic potential. The identification of the γ-subunit provides additional local targets for targeted inhibition.
Solution Approach 2:
The patent replaces the need for complex whole-complex structural studies with focused biochemical and biophysical characterization of individual domains and subunits. This substitution allows detailed mechanistic understanding of specific enzymatic steps without requiring complete structural elucidation of the entire dynamic complex, facilitating practical inhibitor design.
3Productivity
If recombinant polypeptides are produced, then control of fatty acid synthesis is improved, but production complexity increases
Solution Approach 1:
The patent produces recombinant polypeptides corresponding to specific functional domains (e.g., KR domain, ER domain, γ-subunit) rather than the entire FAS complex. This segmentation simplifies production by allowing independent expression and purification of individual components, reducing overall production complexity while maintaining the ability to control fatty acid synthesis through targeted enzyme production.
Data Source
AI summary
In a first aspect, the present invention relates to new recombinant polypeptides derived from the newly identified gamma subunit of the fatty acid synthase protein complex. In addition, a fatty acid synthase protein complex comprising these new recombinant polypeptides are disclosed as well as nucleic acid molecules encoding these polypeptides. Further, a host cells containing the nucleic acid molecule encoding the polypeptides according to the present invention or expressing the polypeptide according to the present invention are described. In addition, an isolated fatty acid synthase protein complex is disclosed containing the newly identified gamma subunit thereof. Moreover, methods for determining the suitability of candidate compounds capable of inhibiting either the ketoreductase, enoylreductase or malonyl/palmitoyl transferase present in the FAS protein complex and methods for designing inhibitors of said enzymes are disclosed. Finally, the present invention relates to the inhibitors and their use in medicinal applications.